Expression and immunogenicity study of IBV S1 fusion protein containing FAdV-4 Fiber 2 B cell epitopes
- VernacularTitle:含有FAdV-4 Fiber 2 B细胞表位的IBV S1融合蛋白的表达及免疫原性
- Author:
Yaru GAO
1
;
Yang WANG
1
;
Hanwen ZHANG
1
;
Lin LIU
1
;
Xiaoyang CAO
1
;
Jingrui LIU
1
;
Bingjie LI
1
;
Jingjing CHANG
1
;
Yapeng SONG
1
;
Wenming GAO
1
;
Xinsheng LI
1
Author Information
- Publication Type:Journal Article
- Keywords: B cell epitope; FAdV-4; fiber 2; infectious bronchitis; fusion protein
- From: Chinese Journal of Veterinary Science 2025;45(8):1616-1623
- CountryChina
- Language:Chinese
- Abstract: To verify whether the two B-cell epitopes Pep1 and Pep4 in the FAdV-4 WZ fiber can be used as candidate epitopes for multivalent epitope vaccines,epitopes Pep1 and Pep4 were tandemly linked with the chicken infectious bronchitis virus strain M41 S1 protein gene in different patterns,and a recombinant fusion plasmid was constructed and expressed in E.coli BL21(DE3).It was confirmed by Western blot and ELISA tests that all four expressed fusion proteins reacted specific-ally with anti-M41 whole virus serum and WZ strain anti-Fiber 2-knob protein serum.After purifi-cation and immunization of BALB/c mice,specific antibodies against the peptide epitopes were de-tected in mouse sera.The results showed that the Pep4 epitope induced a stronger immune re-sponse than the Pep1 epitope.When Pep1 was connected with the amino and carboxyl termini of the fusion protein,respectively,both resulted in the production of the same level of anti-Pep1 anti-bodies in the immunized animals,whereas when Pep4 was connected with the carboxyl terminus of the fusion protein,the immunized animals produced a higher level of anti-Pep4-specific antibodies.This research indicates that the B cell epitopes Pep1 and Pep4 of the reactive WZ strain Fiber 2,when conjugated with proteins to form fusion proteins,can enhance the immunogenicity of Pep1 and Pep4 without affecting the antigenicity of the carrier protein.This study provides technical support and serves as a reference for the design and development of a multivalent epitope vaccine for FAdV-4.
